Association of HER2 amplification or overexpression with overall survival in advanced upper gastrointestinal adenocarcinomas
HER2+ and treatment with trastuzumab in HER2+ patients were associated with superior OS in upper gastrointestinal adenocarcinomas across molecular subgroups except that of mutKRAS. These results reaffirm the importance of anti-HER2 treatment in HER2+ patients and provide insight on the prognostic and biological divergence among these anatomically linked upper gastrointestinal adenocarcinomas.
Authors
- Pamela Tse (ORCID: https://orcid.org/0009-0005-3494-8320)
- Dean W. Felsher (ORCID: https://orcid.org/0000-0003-2496-523X)
- Laurel A. Habel (ORCID: https://orcid.org/0000-0002-7230-587X)
- Minggui Pan (ORCID: https://orcid.org/0000-0002-8368-6524)
- George A. Fisher (ORCID: https://orcid.org/0000-0002-6828-3938)
- Sachdev Thomas (ORCID: https://orcid.org/0000-0003-3867-2454)
- Ninah Achacoso
- Elaine Chung (ORCID: https://orcid.org/0009-0003-7267-9235)
- Alexander Dang (ORCID: https://orcid.org/0000-0002-7964-7426)
- Aleyda V. Solorzano
- Jeffrey Y. Bien (ORCID: https://orcid.org/0000-0002-3111-5674)
- Chen Jiang (ORCID: https://orcid.org/0000-0002-0336-4518)
- Vishnu P Kanakaveti
- Meng Tong (ORCID: https://orcid.org/0000-0001-8244-0277)
- Tina Huang (ORCID: https://orcid.org/0000-0003-3818-6894)
- John Stover
Institutions
- Kaiser Permanente (US)
- Kaiser Permanente Vallejo Medical Center (US)
- Stanford University (US)
Publication Details
- Journal
- BJC Reports
- Published
- 2025-05-14
- DOI
- https://doi.org/10.1038/s44276-025-00148-z
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Kaiser Permanente